Trial Profile
A Randomized, Controlled Trial on Dexmedetomidine for Providing Adequate Sedation and Preserved Neurologic Examination for Endovascular Treatment of Acute Ischemic Stroke or Cerebral Vasospasm
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary) ; Fentanyl; Midazolam
- Indications Sedation
- Focus Therapeutic Use
- 15 Apr 2022 Status changed from recruiting to discontinued.
- 15 May 2015 New trial record